Kamada Ltd (KMDA) — SEC Filings

Kamada Ltd (KMDA) — 42 SEC filings. Latest: 6-K (May 6, 2026). Includes 33 6-K, 4 4, 3 SC 13G/A.

View Kamada Ltd on SEC EDGAR

Overview

Kamada Ltd (KMDA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 4 filed on Apr 9, 2026: On April 7, 2026, Kamada Ltd. reported a change in beneficial ownership of securities. The filing details transactions related to the company's stock, with specific changes noted for reporting persons. The exact nature of the transactions and the individuals involved are detailed within the full fil

Sentiment Summary

Across 42 filings, the sentiment breakdown is: 7 bullish, 34 neutral, 1 mixed. The dominant filing sentiment for Kamada Ltd is neutral.

Filing Type Overview

Kamada Ltd (KMDA) has filed 4 4, 33 6-K, 2 20-F, 3 SC 13G/A with the SEC between Feb 2024 to May 2026.

Filings by Year

2026 · 2025 · 2024

Recent SEC Filings (42)

Kamada Ltd SEC Filing History
DateFormDescriptionRisk
May 6, 20266-K6-K Filing
Apr 9, 202644 Filing
Apr 9, 20264Kamada Ltd. Reports Beneficial Ownership Changelow
Apr 9, 20264Kamada Ltd. Insider Reports Ownership Changelow
Apr 9, 20264Kamada Ltd. Insider Reports Stock Ownership Changelow
Mar 31, 20266-KKamada Ltd. Updates Dividend Withholding Tax Procedureslow
Mar 26, 20266-KKAMADA: FDA APPROVES SAN ANTONIO PLASMA COLLECTION CENTER
Dec 18, 20256-KKamada Ltd. Extends Canadian Supply Tender by $10-14Mlow
Dec 10, 20256-KKamada Ltd. Holds Annual Shareholder Meetinglow
Dec 8, 20256-KKamada Discontinues Phase 3 Trial, Still Eyes 2026 Growthmedium
Nov 10, 20256-KKamada Ltd. Files 6-K with Q3 & 9-Month 2025 Resultslow
Nov 4, 20256-K6-K Filing
Oct 23, 20256-KKamada Ltd. Sets December 10th Annual Shareholder Meetinglow
Sep 2, 20256-KKamada Ltd. to Attend September Investor Conferenceslow
Aug 13, 20256-KKamada Ltd. Reports Strong Q2 and H1 2025 Financial Resultslow
Aug 11, 20256-KKamada Ltd. Secures FDA Approval for Houston Plasma Centerlow
Aug 6, 20256-KKamada Ltd. to Report Q2 2025 Financials Aug 13low
Jun 17, 20256-KKamada Ltd. Confirms Global Operations and Product Availabilitylow
May 14, 20256-KKamada Ltd. Files Q1 2025 Results, Incorporates into S-8 Filingslow
May 7, 20256-KKamada Ltd. to Report Q1 2025 Results on May 14low

Risk Profile

Risk Assessment: Of KMDA's 36 recent filings, 0 were flagged as high-risk, 4 as medium-risk, and 32 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

  • RECANATI LEON
  • Orlev Chaime
  • Davidi Ishay
  • 0001426753
  • Nir Livneh
  • Amir London

Industry Context

Kamada Ltd. operates in the pharmaceutical preparations industry, focusing on the development and commercialization of plasma-derived protein therapeutics.

Top Tags

registration-statement (9) · sec-filing (7) · filing-update (7) · financial-results (7) · corporate-governance (4) · earnings-announcement (4) · ownership-change (3) · pharmaceuticals (3) · guidance (3) · shareholder-meeting (3)

Key Numbers

Kamada Ltd Key Metrics
MetricValueContext
Period of Report2026-04-07Date of ownership change
Filing Date2026-04-09Date the report was filed with the SEC
Canadian Supply Tender Extension$10-14MRepresents potential additional revenue for Kamada Ltd.
Projected Growth 2026Double-digitKamada projects double-digit growth in revenues and profitability for the upcoming year.
Reporting PeriodQ1 2025Financial results for the first quarter of 2025 are being reported.
Fiscal Year End2024The report covers the company's performance up to December 31, 2024.
Contract Value$25MTotal revenue expected from the 3-year supply agreement in Latin America.
Contract Duration3-YearLength of the agreement for supplying KAMRAB® and VARIZIG®.
Financial Guidance Year2024Kamada Ltd. affirmed its financial guidance for this year.
Projected Growth Year2025Kamada Ltd. expects continued double-digit profitable growth for this year.
Third QuarterQ3 2024Reporting period for profitable growth
Nine Month PeriodNine Month 2024Reporting period for profitable growth
6-Month Top-Line Growth18%Year-over-year increase in revenue for the first half of 2024.
6-Month Profitability Increase68%Year-over-year increase in profitability for the first half of 2024.
Q1 2024 Revenue Growth23%Year-over-year increase indicating strong sales performance.

Forward-Looking Statements

  • {"claim":"Phoenix Holdings Ltd. will maintain a significant stake in Kamada Ltd. for the foreseeable future.","entity":"Phoenix Holdings Ltd.","targetDate":"December 31, 2024","confidence":"medium"}

Frequently Asked Questions

What are the latest SEC filings for Kamada Ltd (KMDA)?

Kamada Ltd has 42 recent SEC filings from Feb 2024 to May 2026, including 33 6-K, 4 4, 3 SC 13G/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of KMDA filings?

Across 42 filings, the sentiment breakdown is: 7 bullish, 34 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Kamada Ltd SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Kamada Ltd (KMDA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Kamada Ltd?

Financial highlights for Kamada Ltd are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.

What is the investment thesis for KMDA?

The investment thesis for KMDA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Kamada Ltd?

Key executives identified across Kamada Ltd's filings include RECANATI LEON, Orlev Chaime, Davidi Ishay, 0001426753, Nir Livneh and 1 others.

What are the main risk factors for Kamada Ltd stock?

Of KMDA's 36 assessed filings, 0 were flagged high-risk, 4 medium-risk, and 32 low-risk.

What are recent predictions and forward guidance from Kamada Ltd?

Recent forward-looking statements from Kamada Ltd include guidance on {"claim":"Phoenix Holdings Ltd. will maintain a significant stake in Kamada Ltd. for the foreseeable future.","entity":".

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.